Pharmaceutical company HYTN Innovations has announced the successful export of cannabis to Canadian medical cannabis company 4C LABS in the UK.
HYTN Innovations specialises in developing, formulating and manufacturing psychoactive and psychotropic compounds, including cannabis and psilocybin.
The company’s move follows HYTN’s recent achievement of receiving its first international order for products manufactured under its Good Manufacturing Practices (GMP) certification.
The shipment of this first order includes the successful export, import, packaging, and release of 43.75kg of cannabis flower for medical use.
The initial order, announced last month, has been paid in full, and the products are now available to UK patients through the regulated medical sales model.
In September this year, HYTN Innovations partnered with 4C LABS to manufacture and export bulk cannabis products for distribution in the UK and global markets.
Building on this success, HYTN Innovations has received new orders for over 500kgs of additional cannabis products, highlighting the growing demand for its cannabis-based pharmaceuticals in international markets.
HYTN Innovations chief operations officer Jason Broome said: “The fulfilment of our first order to 4C LABS and the subsequent substantial orders highlight the trust and confidence our partners place in our products and the strength and efficiency of our GMP standards.
“We are committed to stabilising international supply lines and ensuring that our products meet or exceed the regulatory requirements of international markets.”
HYTN’s products are manufactured under GMP standards, ensuring compliance with quality requirements for international markets.
This milestone supports the pharmaceutical firm’s goal to expand its global presence and deliver cannabis products to patients worldwide.
4C LABS is focused on creating a vertically integrated, quality-driven infrastructure to supply cannabis products to the UK, European Union (EU), and other regulated international markets.
The company focuses on launching products in these markets while also emphasising research and development of plant-based therapeutic products for its growing catalogue.
